respiratori
virus
mainli
human
rhinovirus
hrv
major
trigger
exacerb
asthmat
children
virus
first
target
airway
epitheli
cell
aec
antigenpres
cell
apc
includ
convent
plasmacytoid
dendrit
cell
cdc
pdc
respect
via
mobil
pattern
recognit
receptor
prr
tolllik
receptor
tlr
rna
helicas
rigi
hrv
induc
innat
interferon
ifn
product
aec
via
rigi
wherea
influenza
viru
requir
impair
antivir
respons
report
asthmat
patient
infect
hrv
shown
alter
product
type
ifn
andor
type
iii
ifn
interleukin
il
howev
defici
ifn
respons
report
sever
asthma
associ
defect
tlr
activ
observ
well
control
asthma
knowledg
data
avail
regard
express
function
prr
exacerb
hypothes
alter
express
andor
function
viru
sensor
associ
impair
innat
immun
respons
virusinduc
asthma
exacerb
moreov
alter
might
impact
clinic
inflammatori
profil
test
hypothesi
antivir
respons
express
function
viru
sensor
blood
mononuclear
cell
explor
cohort
allerg
asthmat
children
admit
hospit
diagnosi
sever
exacerb
evalu
also
includ
clinic
featur
airway
blood
inflamm
done
exacerb
repeat
steadi
state
week
later
first
compar
viru
infect
notinfect
patient
exacerb
secondli
result
show
infect
differ
viru
frequent
detect
asthmat
patient
steadi
state
focus
virusinfect
patient
exacerb
order
compar
patient
infect
time
infect
exacerb
data
demonstr
impair
ifn
product
viru
sensor
function
mainli
observ
subgroup
asthmat
children
reinfect
steadi
state
multicent
prospect
studi
approv
region
investig
review
board
de
protect
de
personn
nord
ouest
ref
involv
pediatr
depart
lill
univers
hospit
lill
franc
roubaix
hospit
roubaix
franc
parent
written
inform
consent
obtain
children
children
age
year
diagnosi
allerg
asthma
admit
hospit
sever
exacerb
elig
inclus
sever
exacerb
assess
accord
guidelin
patient
treat
system
corticosteroid
allerg
sensitis
defin
least
one
allergenspecif
ige
kual
andor
posit
skin
prick
test
exclus
criteria
congenit
acquir
chronic
ill
asthma
subject
assess
twice
exacerb
hospit
steadi
state
followup
visit
schedul
week
later
week
baselin
characterist
includ
demograph
characterist
person
comorbid
allerg
rhiniti
atop
dermat
food
allergi
histori
asthma
exacerb
passiv
tobacco
exposur
record
mainten
treatment
document
inhal
corticosteroid
dose
express
fluticason
equival
per
day
length
oxygenotherapi
day
hospit
day
collect
viral
statu
local
sputum
system
ifn
respons
inflammatori
reaction
cytokin
sputum
inflammatori
cell
count
prr
express
function
studi
time
steadi
state
asthma
control
evalu
spirometri
perform
asthma
control
assess
accord
gina
criteria
well
control
partial
control
uncontrol
wwwginasthmacom
spirometri
bronchodil
revers
measur
accord
american
thorac
societi
european
respiratori
societi
recommend
forc
vital
capac
fvc
express
percentag
predict
valu
vp
fvc
absolut
valu
exhal
nitric
oxid
eno
also
measur
express
ppb
subject
first
group
compar
accord
viral
infect
exacerb
infect
v
notinfect
v
patient
follow
descript
patient
infect
exacerb
steadi
state
v
v
patient
compar
subgroup
patient
infect
exacerb
v
v
patient
low
number
patient
infect
steadi
state
among
v
patient
allow
studi
subgroup
spontan
induc
sputum
peripher
blood
mononuclear
cell
pbmc
plasma
collect
exacerb
first
day
steadi
state
plasma
blood
sampl
use
measur
cytokin
concentr
blood
mononuclear
cell
mnc
isol
use
ficollpaqu
densiti
gradient
wash
cell
resuspend
rpmi
supplement
heatinactiv
fetal
calf
serum
antibiot
life
technolog
pb
heatinactiv
fetal
calf
serum
cell
cultur
flow
cytometri
respect
isol
mnc
stimul
ligand
synthet
doublestr
rna
poli
ic
ligand
rnahelicas
liposomepoly
lipop
c
ligand
guardiquimod
phytohemagglutinin
pha
posit
control
invivogen
san
diego
ca
supernat
collect
h
cultur
induc
sputum
sampl
collect
nebul
isoton
exacerb
hyperton
steadi
state
salin
solut
previous
describ
plug
isol
sputum
weight
process
previous
describ
briefli
plug
dilut
sputolysin
vwr
sputum
fluid
cell
separ
centrifug
isol
cell
use
differenti
cell
count
fluid
cytokin
measur
cytospin
prepar
cell
pellet
supernat
store
sampl
squamou
cell
exclud
analysi
differenti
leukocyt
cell
count
undertaken
count
nonsquam
cell
sputum
sampl
nasal
secret
collect
patient
inclus
exacerb
steadi
state
sampl
frozen
rna
extract
commerci
avail
multiplex
revers
chain
reaction
rtpcr
screen
respiratori
viral
pathogen
includ
influenza
viru
b
respiratori
syncyti
viru
b
adenoviru
metapneumoviru
coronaviru
parainfluenza
viru
rhinoviru
abc
enteroviru
bocaviru
seeplex
ace
detect
seegen
seoul
korea
specimen
detect
rhinoviru
type
amplif
sequenc
viral
protein
vp
region
use
primer
describ
wisdom
et
al
quantit
hrv
rna
perform
accord
tapparel
et
al
briefli
one
step
realtim
rt
pcr
perform
use
quantitect
probe
rtpcr
kit
qiagen
primer
probe
agcctgcgtggckgcc
cylnaagcclnatgcgtgg
famctccggcccctgaatgyggctaatamra
gaaacacggacacccaaagtagt
reaction
run
taqman
appli
biosystem
thermocycl
follow
cycl
condit
min
min
cycl
min
rhinoviru
propag
cell
supernat
quantifi
rna
cultur
supernat
extract
serial
dilut
submit
quantit
rt
pcr
order
establish
standard
curv
quantif
result
quantif
express
equival
analyz
activ
express
prr
rigi
within
blood
dc
monocyt
pbmc
incub
min
ice
isotypematch
control
antibodi
lymphocyt
granulocyt
dc
hladr
monocyt
monocyt
defin
cell
cdc
pdc
subset
respect
defin
hladr
hladr
phenotyp
illustr
addit
file
cell
activ
apc
analyz
measur
median
fluoresc
mfi
hladr
bdbioscienc
moreov
express
rigi
santacruz
biotechnolog
estim
indirect
label
cell
permeabil
correspond
isotyp
control
includ
defin
background
level
result
express
subtract
valu
obtain
isotyp
control
pbmc
stimul
ligand
polyinosin
polycytidyl
acid
poli
c
rnahelicas
poli
c
liposom
lipopoli
c
gardiquimod
invivogen
san
diego
ca
pbmc
supernat
collect
baselin
h
stimul
level
cytokin
r
system
abingdon
uk
ebiosci
san
diego
ca
elabsci
biot
wuhan
china
plasma
sputum
fluid
supernat
pbmc
measur
elisa
whole
popul
p
c
increas
secret
compar
cell
medium
alon
wherea
gardiquimod
lipop
c
upregul
level
data
shown
statist
analys
perform
sa
softwar
sa
institut
inc
cari
nc
qualit
variabl
report
number
percentag
compar
via
chisquar
test
fisher
exact
test
continu
variabl
report
median
interquartil
rang
iqr
compar
via
mannwhitney
test
normal
assess
via
shapirowilk
test
pvalu
consid
statist
signific
evalu
magnitud
differ
group
calcul
absolut
standard
differ
standard
differ
higher
denot
low
medium
larg
imbal
respect
first
v
compar
v
patient
exacerb
steadi
state
second
step
v
v
compar
v
v
patient
exacerb
condit
compar
steadi
state
group
v
v
v
v
v
v
seventytwo
patient
median
age
year
iqr
boy
includ
tabl
among
mainten
treatment
inclus
viru
detect
patient
hrv
fig
median
hrv
load
equival
clinic
featur
exacerb
similar
v
v
patient
tabl
see
addit
file
sixtysix
patient
evalu
steadi
state
none
symptom
exacerb
accord
gina
asthma
well
control
patient
tabl
viru
identifi
patient
includ
without
infect
exacerb
fig
differ
virus
detect
exacerb
steadi
state
v
v
patient
previous
report
moreov
repartit
inclus
year
differ
among
v
v
patient
well
v
v
v
v
patient
see
addit
file
similar
level
detect
sputum
fig
plasma
see
addit
file
v
v
patient
exacerb
steadi
state
time
v
patient
significantli
higher
level
sputum
fig
plasma
see
addit
file
v
patient
level
associ
higher
percentag
sputum
eosinophil
p
fig
eosinophil
percentag
significantli
correl
level
sputum
r
p
plasma
r
p
ns
contrast
sputum
neutrophil
percentag
number
differ
v
v
fig
tabl
exacerb
level
significantli
greater
sputum
fig
plasma
v
patient
see
addit
file
trend
toward
increas
level
sputum
also
observ
plasma
level
significantli
lower
v
patient
steadi
state
wherea
level
cytokin
includ
differ
see
addit
file
data
shown
compar
steadi
state
level
sputum
v
patient
significantli
higher
exacerb
see
addit
file
express
level
rigi
blood
dc
monocyt
similar
v
v
patient
time
see
addit
file
express
costimulatori
molecul
greater
cdc
monocyt
v
v
patient
exacerb
pdc
steadi
state
p
fig
contrast
hladr
level
similar
compar
v
increas
unstimul
pbmc
v
p
see
addit
file
respons
prr
ligand
level
higher
gardiquimod
ligand
stimul
pbmc
v
patient
time
point
wherea
level
remain
similar
whatev
stimulu
see
addit
file
exacerb
level
greater
gardiquimodstimul
pbmc
among
v
patient
p
wherea
level
lower
p
fig
steadi
state
level
higher
poli
c
ligand
stimul
pbmc
among
v
patient
p
see
addit
file
compar
steadi
state
level
exacerb
lower
unstimul
poli
c
stimul
pbmc
among
v
v
patient
see
addit
file
product
unstimul
pbmc
v
patient
secret
gardiquimodstimul
pbmc
also
lower
p
cytokin
chang
compar
v
v
patient
sputum
level
p
exacerb
lower
v
v
patient
signific
chang
fig
plasma
level
lower
v
v
wherea
concentr
greater
p
level
differ
fig
steadi
state
level
p
p
ns
lower
v
v
patient
sputum
fig
concentr
blood
ifn
similar
v
v
v
v
patient
steadi
state
see
addit
file
sputum
concentr
lower
v
v
v
v
patient
period
p
fig
wherea
eosinophil
differ
contrast
percentag
neutrophil
significantli
higher
v
v
patient
steadi
state
p
tabl
exacerb
steadi
state
sputum
concentr
p
higher
v
v
v
v
patient
fig
higher
level
detect
sputum
v
v
patient
steadi
state
p
fig
final
plasma
concentr
greater
v
v
v
v
patient
exacerb
p
wherea
differ
cytokin
sputum
plasma
see
addit
file
comparison
steadi
state
exacerb
among
v
v
v
v
group
reveal
plasma
sputum
cytokin
level
differ
exacerb
steadi
state
v
v
cdc
monocyt
express
significantli
v
v
patient
fig
see
addit
file
exacerb
rigi
express
higher
cdc
pdc
monocyt
v
v
patient
p
fig
differ
hladr
see
addit
file
secret
cytokin
unstimul
pbmc
similar
v
v
v
v
patient
time
see
addit
file
product
respons
gardiquimod
significantli
lower
pbmc
v
v
patient
exacerb
p
see
addit
file
secret
respons
poli
c
lipopoli
c
also
significantli
decreas
fig
steadi
state
trend
observ
lipopoli
c
induc
product
fig
p
p
ns
see
addit
file
level
cytokin
differ
group
compar
steadi
state
level
significantli
lower
poli
c
stimul
pbmc
exacerb
v
v
patient
v
v
patient
see
addit
file
observ
product
gardiquimodstimul
pbmc
p
studi
design
assess
alter
viru
sensor
associ
impair
innat
immun
respons
virusinduc
asthma
exacerb
children
test
hypothesi
patient
control
analyz
accord
viral
statu
focus
work
previous
describ
subgroup
prone
viral
reinfect
v
v
patient
evalu
exacerb
steadi
state
distinguish
inflamm
induc
exacerb
one
due
asthma
done
studi
exacerb
trigger
viru
children
among
hrv
type
c
commonli
identifi
first
observ
clinic
characterist
differ
group
patient
differ
time
shown
level
v
differ
v
patient
low
product
type
iii
interferon
aec
alveolar
macrophag
experiment
infect
hrv
report
asthmat
children
adult
profound
sever
atop
asthma
present
studi
patient
infect
hrv
appear
display
impair
data
shown
contrast
bergauer
et
al
recent
report
level
markedli
increas
small
cohort
hrvinfect
symptomat
asthmat
children
year
compar
infect
asymptomat
patient
wherea
synthesi
remain
unchang
result
suggest
product
alter
virusinduc
exacerb
asthmat
children
compar
studi
popul
differ
bergauer
et
al
age
also
sever
exacerb
furthermor
result
seem
inconsist
larger
cohort
last
v
patient
alter
antivir
respons
link
modif
express
prr
blood
dc
monocyt
blockad
function
result
might
also
suggest
alter
antivir
respons
might
preferenti
observ
airway
compar
blood
cell
antivir
respons
analyz
among
v
patient
observ
v
v
patient
infect
time
produc
lower
level
v
v
patient
exacerb
product
also
lower
steadi
state
despit
presenc
new
viru
compar
v
v
rnahelicas
overexpress
circul
apc
v
v
patient
exacerb
pbmc
show
alter
product
rigi
activ
might
facilit
viral
reinfect
accord
function
product
respons
ligand
also
impair
suggest
defect
function
receptor
pbmc
v
v
patient
recent
report
alveolar
macrophag
product
impair
may
due
alter
signal
differ
mechan
might
respons
defect
product
transform
growth
inhibit
ifn
product
respons
hrv
implic
suppressor
cytokin
signal
soc
overexpress
airway
epithelium
sever
asthmat
children
suggest
although
controversi
data
suggest
specif
alter
antivir
respons
relat
dysfunct
viru
sensor
character
reinfect
patient
viral
infect
exacerb
also
impact
airway
inflamm
shown
persist
increas
sputum
eosinophilia
correl
concentr
agreement
norzila
et
al
cytokin
alter
innat
immun
respons
viral
infect
favor
develop
specif
inflammatori
reaction
v
v
lack
increas
level
suggest
virusinfect
directli
influenc
subgroup
nevertheless
report
viral
infect
allerg
environ
induc
synthesi
cell
probabl
due
prr
activ
dc
interestingli
product
stimul
prime
pbmc
v
patient
result
probabl
due
v
v
subgroup
concomitantli
dc
activ
exacerb
demonstr
overexpress
contribut
apc
propens
induc
secret
lymphocyt
infect
patient
link
inflamm
antivir
respons
also
illustr
restor
product
plasmacytoid
dc
allerg
asthmat
children
treat
omalizumab
reinfect
patient
inflammatori
reaction
character
strong
secret
might
involv
neutrophil
recruit
observ
steadi
state
featur
also
associ
product
promot
smooth
muscl
cell
prolifer
interestingli
simpson
et
al
report
adult
asthmat
neutrophil
inflamm
high
level
sputum
reduc
abil
produc
respons
hrv
suggest
link
popul
group
v
v
children
long
term
followup
need
defin
specif
inflamm
mostli
relat
repeat
viral
infect
result
support
pronounc
defect
secret
virustrigg
exacerb
asthmat
children
prone
viral
reinfect
defect
associ
overexpress
viru
sensor
defect
respons
correspond
ligand
specif
airway
inflamm
benefit
strategi
integr
antivir
approach
subgroup
patient
explor
